Clinical Trials · NCT00600886
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 358
- Start date
- Feb 2008
- Locations
- 95 sites, 27 countries
- Primary endpoint
- Percentage of Participants With a Reduction of Mean GH Level to <2.5 μg/L and the Normalization of IGF-1